Risk of CNS dissemination in extranodal lymphomas

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages

  Ferreri, Andrés J M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CANCER; ADRENAL LYMPHOMA; BONE CANCER; BONE LYMPHOMA; BREAST CANCER; BREAST LYMPHOMA; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; GASTROINTESTINAL LYMPHOMA; GYNECOLOGIC CANCER; GYNECOLOGIC LYMPHOMA; HEAD AND NECK CANCER; HEAD AND NECK LYMPHOMA; HEPATOSPLENIC LYMPHOMA; HIGH RISK PATIENT; HIV ASSOCIATED EXTRANODAL LYMPHOMA; HUMAN; INTRAOCULAR LYMPHOMA; KIDNEY CANCER; LARGE CELL LYMPHOMA; LIVER CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NASAL CAVITY LYMPHOMA; NASOPHARYNX CANCER; NASOPHARYNX LYMPHOMA; NONHODGKIN LYMPHOMA; NOSE CAVITY CANCER; OCULAR ADNEXAL LYMPHOMA; ORBIT CANCER; ORBIT LYMPHOMA; PARANASAL SINUS CANCER; PARANASAL SINUS LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RENAL LYMPHOMA; REVIEW; RISK ASSESSMENT; SKIN LYMPHOMA; SOFT TISSUE CANCER; SOFT TISSUE LYMPHOMA; SPLEEN CANCER; T CELL LYMPHOMA; THORACIC LYMPHOMA; THORAX CANCER; TONGUE CANCER; TONGUE LYMPHOMA; TONSIL CANCER; TONSIL LYMPHOMA;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, NON-HODGKIN; PATIENT SELECTION; PROGNOSIS; RISK FACTORS;

EID: 84897048820     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70568-0     Document Type: Review

References (110)

1. Kridel R, Dietrich PY Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011, 12:1258-1266.
2. Hollender A, Kvaloy S, Lote K, Nome O, Holte H Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000, 36:1762-1768.
3. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000, 11:685-690.
4. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012, 23:1267-1273.
5. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007, 18:149-157. the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
6. Harbour R, Miller J A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336.
7. Madge SN, McCormick A, Patel I, et al. Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes. Eye (Lond) 2010, 24:954-961.
8. Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol 2007, 31:170-184.
9. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005, 131:193-200.
10. Jenkins C, Rose GE, Bunce C, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye (Lond) 2003, 17:809-820.
11. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 2007, 18:1851-1855.
12. Ferreri AJ How I treat primary CNS lymphoma. Blood 2011, 118:510-522.
13. Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003, 26:6-11.
14. Hausdorff J, Davis E, Long G, et al. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am 1997, 3:303-311.
15. Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?. Ann Oncol 2010, 21:1058-1063.
16. Li S, Feng X, Li T, et al. Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol 2013, 37:14-23.
17. Cortelazzo S, Mian M, Oldani A, et al. Primary extranodal diffuse large B-cell lymphoma (DLBCL) arising in distinct sites of head and neck have different clinical characteristics and outcome. Haematologica 2007, 92(suppl 1):269. (abstr).
18. Oprea C, Cainap C, Azoulay R, et al. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol 2005, 131:468-471.
19. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005, 46:1721-1727.
20. Mian M, Ferreri AJ, Rossi A, et al. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. Leuk Lymphoma 2013, 54:62-68. the International Extranodal Lymphoma Study Group (Ielsg).
21. de Leval L, Bonnet C, Copie-Bergman C, et al. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Ann Oncol 2012, 23:3143-3151.
22. Castillo JJ, Reagan JL Plasmablastic lymphoma: a systematic review. ScientificWorldJournal 2011, 11:687-696.
23. Sato Y, Onishi N, Morito T, et al. Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype. Cancer Sci 2009, 100:42-46.
24. Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000, 24:623-639.
25. Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993, 11:2306-2313.
26. Wilson WH, Grant C, Dunleavy K Therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013, 369:283-284.
27. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999, 17:2479-2485.
28. Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol 2013, 31:10-17.
29. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol 2007, 25:3915-3922.
30. Kabiawu-Ajise OE, Harris J, Ismaili N, Amorosi E, Ibrahim S Primary effusion lymphoma with central nervous system involvement in an HIV-negative homosexual male. Acta Haematol 2012, 128:77-82.
31. Narimatsu H, Ota Y, Kami M, et al. Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 2007, 18:122-128.
32. Patsalides AD, Atac G, Hedge U, et al. Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology 2005, 237:265-273.
33. Dunleavy K, Chattopadhyah P, Kawada J Immune characteristics associated with lymphomatoid granulomatosis and outcome following treatment with interferon-alpha. Blood 2010, 116:963. (abstr).
34. Ishiura H, Morikawa M, Hamada M, et al. Lymphomatoid granulomatosis involving central nervous system successfully treated with rituximab alone. Arch Neurol 2008, 65:662-665.
35. Petrella TM, Walker IR, Jones GW, Leber B Radiotherapy to control CNS lymphomatoid granulomatosis: a case report and review of the literature. Am J Hematol 1999, 62:239-241.
36. Ghimire P, Wu GY, Zhu L Primary gastrointestinal lymphoma. World J Gastroenterol 2011, 17:697-707.
37. Tutt AN, Brada M, Sampson SA Enteropathy associated T cell lymphoma presenting as an isolated CNS lymphoma three years after diagnosis of coeliac disease: T cell receptor polymerase chain reaction studies failed to show the original enteropathy to be a clonal disorder. Gut 1997, 40:801-803.
38. Pfaender M, D'Souza WJ, Trost N, Litewka L, Paine M, Cook M Visual disturbances representing occipital lobe epilepsy in patients with cerebral calcifications and coeliac disease: a case series. J Neurol Neurosurg Psychiatry 2004, 75:1623-1625.
39. Loganathan S, Zaitoun A, Charlton CP Lymphoma with central nervous system involvement in a young patient with Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr 2010, 51:790-792.
40. Ponzoni M, Ferreri AJ, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007, 25:3168-3173.
41. Ferreri AJ, Dognini GP, Govi S, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?. J Clin Oncol 2008, 26:5134-5136.
42. De Renzo A, Perna F, Persico M, et al. Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma. Eur J Haematol 2008, 81:51-57.
43. Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer 2001, 92:2023-2029.
44. Kashimura M, Noro M, Akikusa B, et al. Primary splenic diffuse large B-cell lymphoma manifesting in red pulp. Virchows Arch 2008, 453:501-509.
45. Ferreri AJ, Govi S, Pileri SA Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 2012, 83:283-292.
46. Harada Y, Kato S, Komiya H, Shirota T, Mukai K, Hayashi T Primary omental gamma/delta T-cell lymphoma involving the central nervous system. Leuk Lymphoma 2004, 45:1947-1950.
47. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003, 102:4261-4269.
48. Thai A, Prindiville T Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohn's Colitis 2010, 4:511-522.
49. Voss MH, Lunning MA, Maragulia JC, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013, 13:8-14.
50. Aviv A, Tadmor T, Polliack A Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol 2013, 24:2236-2244.
51. Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer 2008, 8:86.
52. Yhim HY, Kang HJ, Choi YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer 2010, 10:321-332.
53. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008, 19:233-241. the International Extranodal Lymphoma Study Group.
54. Salzberg M, Maragulia J, Press O, et al. Primary breast diffuse large B cell lymphoma: a distinct clinical entity. Blood 2012, 120:1618-1619. (abstr).
55. Avilés A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005, 69:256-260.
56. Caon J, Wai ES, Hart J, et al. Treatment and outcomes of primary breast lymphoma. Clin Breast Cancer 2012, 12:412-419.
57. Aviles A, Neri N, Nambo MJ The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol 2012, 35:126-129.
58. Signorelli M, Maneo A, Cammarota S, et al. Conservative management in primary genital lymphomas: the role of chemotherapy. Gynecol Oncol 2007, 104:416-421.
59. Kim YR, Kim JS, Min YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol 2012, 5:49. 28.
60. Grigg AP, Connors JM Primary adrenal lymphoma. Clin Lymphoma 2003, 4:154-160.
61. Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011, 96:1002-1007.
62. Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012, 103:245-251.
63. Horiguchi K, Hashimoto K, Hashizume M, et al. Primary bilateral adrenal diffuse large B-cell lymphoma demonstrating adrenal failure. Intern Med 2010, 49:2241-2246.
64. Mozos A, Ye H, Chuang WY, et al. Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Mod Pathol 2009, 22:1210-1217.
65. Vélayoudom FL, Cardot-Bauters C, Decouvelaere AV, Vlaeminck V, Bauters F, Wémeau JL Non Hodgkin's lymphoma involving the adrenal glands and the central nervous system (CNS): a particular evolution after chemotherapy. Ann Endocrinol (Paris) 2005, 66:527-531.
66. Markert A, May A, Weber J, Rottenburger C, Rauer S, Veelken H Bilateral renal lymphoma after paraneoplastic limbic encephalitis. J Clin Oncol 2009, 27:1142-1144.
67. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003, 21:20-27. the International Extranodal Lymphoma Study Group.
68. Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011, 29:2766-2772.
69. Sarris A, Vitolo U, Zucca E Prospective management of primary testicular lymphoma (PTL) with doxorubicin-based chemotherapy, prophylactic intrathecal (IT) methotrexate and radiotherapy (RT), but without rituximab: results from IELSG. Blood 2006, 108:2454. (abstr).
70. Bruno Ventre M, Ferreri AJ, Gospodarowicz M, et al. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 Study). Oncologist 2014, published online Feb 24. 10.1634/theoncologist.2013-0249.
71. Messina C, Ferreri AJ, Govi S, et al. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). Br J Haematol 2014, published online Jan 2. 10.1111/bjh.12714.
72. Derenzini E, Casadei B, Pellegrini C, Argnani L, Pileri S, Zinzani PL Non-Hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. Clin Lymphoma Myeloma Leuk 2013, 13:258-265.
73. Monnard V, Sun A, Epelbaum R, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006, 65:817-823.
74. Salvati M, Cervoni L, Artico M, Raco A, Ciappetta P, Delfini R Primary spinal epidural non-Hodgkin's lymphomas: a clinical study. Surg Neurol 1996, 46:339-343.
75. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007, 143:1144-1150.
76. Grange F, Maubec E, Bagot M, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 2009, 145:329-330.
77. Bekkenk MW, Postma TJ, Meijer CJ, Willemze R Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer 2000, 89:913-919.
78. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008, 112:1600-1609. the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomathe International Society for Cutaneous Lymphoma.
79. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
80. Teshima T, Akashi K, Shibuya T, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 1990, 65:327-332.
81. Nomura E, Isoda K, Yamanaka K, Yamaguchi M, Hakamada A, Mizutani H Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. J Dermatol 2005, 32:204-209.
82. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999, 155:483-492.
83. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010, 21:1046-1052.
84. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011, 90:809-818.
85. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010, 116:4283-4290.
86. Bruno-Ventre M, Citterio G, Donadoni G, et al. Risk-tailored CNS prophylaxis in a monoinstitutional series of 194 patients with diffuse large B-cell lymphoma (DLBCL) treated in the rituximab era. Hematol Oncol 2013, 31:169-170. (abstr).
87. Yun J, Kim SJ, Won JH, et al. Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. Leuk Res 2010, 34:1175-1179.
88. Desai J, Mitnick RJ, Henry DH, Llena J, Sparano JA Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. Cancer 1999, 86:1840-1847.
89. Sarker D, Thirlwell C, Nelson M, Gazzard B, Bower M Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003, 17:861-865.
90. Navarro JT, Vall-Llovera F, Mate JL, Morgades M, Feliu E, Ribera JM Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica 2008, 93:149-150.
91. Miralles P, Berenguer J, Ribera JM Diagnosis, prophylaxis and treatment of central nervous system involvement by non-Hodgkin lymphoma in HIV-infected patients. Med Clin (Barc) 2010, 135:417-422. the grupo de estudio de la afección del sistema nervioso central en linfomas asociados a la infección por el virus de la inmunodeficiencia.
92. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003, 21:3948-3954.
93. Boulanger E, Gérard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005, 23:4372-4380.
94. Boulanger E, Daniel MT, Agbalika F, Oksenhendler E Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003, 73:143-148.
95. Andrews JR, Cho-Park YA, Ferry J, Abramson JS, Robbins GK Kaposi's Sarcoma-Associated Herpesvirus-Related Solid Lymphoma Involving the Heart and Brain. Aids Res Treat 2011, 2011:729854.
96. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008, 8:261-267.
97. Mathews MS, Bota DA, Kim RC, Hasso AN, Linskey ME Primary leptomeningeal plasmablastic lymphoma. J Neurooncol 2011, 104:835-838.
98. Castillo JJ, Furman M, Beltrán BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012, 118:5270-5277.
99. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010, 149:675-692. the Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society.
100. Chan TS, Hwang YY, Gill H, et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant 2012, 26:679-683.
101. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009, 27:3354-3362.
102. Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 2013, 13:1512-1522.
103. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005, 37:954-955.
104. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos IS Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. Br J Haematol 2011, 152:72-80.
105. Bruna J, Martínez-Yelamos S, Alonso E, et al. Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma. Int J Hematol 2005, 82:63-65.
106. Stein M, Farrar N, Jones GW, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J 2006, 12:55-62.
107. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004, 15:129-133.
108. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009, 113:3896-3902.
109. Benevolo G, Stacchini A, Spina M, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 2012, 120:3222-3228. the Fondazione Italiana Linfomi.
110. Holte H, Leppä S, Björkholm M, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013, 24:1385-1392.